Articles
Read our latest news and updates.
For media inquiries, contact us at media@compasspathways.com
-
November 15, 2023
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment...
Read article
-
November 02, 2023
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
Read article
-
October 26, 2023
Compass Pathways announces CFO transition
Read article
-
September 18, 2023
Compass Pathways appoints Daphne Karydas to its Board of Directors
Read article
-
September 06, 2023
Compass Pathways announces publication of first study evaluating potential of AI model to predict ou...
Read article
-
August 16, 2023
Compass Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthca...
Read article
-
August 03, 2023
Compass Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
Read article
-
July 25, 2023
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicin...
Read article
-
July 17, 2023
Compass Pathways announces publication of positive data from treatment-resistant depression phase 2 ...
Read article
-
July 13, 2023
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psiloc...
Read article
-
July 06, 2023
American Medical Association Releases Language of First New Current Procedural Terminology Code for ...
Read article
-
July 05, 2023
Compass Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
Read article
-
June 06, 2023
Compass Pathways key patents upheld by the US Patent and Trademark Office
Read article
-
June 01, 2023
Celebrating Pride 2023
Read article
-
May 31, 2023
Compass Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer
Read article
-
May 26, 2023
Data demonstrating long-term improvement in depression in cancer patients following single dose of C...
Read article
-
May 11, 2023
Compass Pathways Announces First Quarter 2023 Financial Results and Business Highlights
Read article
-
May 02, 2023
American Medical Association to Issue First New Code for Psychedelic Therapies
Read article
-
April 06, 2023
Talking to a Principal Investigator on our Phase 3 programme
Read article
-
March 08, 2023
Launching our Diversity Equity and Inclusion (DEI) council
Read article
-
February 28, 2023
Compass Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlight...
Read article
-
February 16, 2023
Compass’s impact strategy
Read article
-
February 10, 2023
Celebrating the International Day of Women and Girls in Science
Read article
-
January 25, 2023
Supporting parents at work
Read article
-
December 15, 2022
Our holiday traditions and reflections
Read article
-
December 08, 2022
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented...
Read article
-
December 01, 2022
Pursuing passions: on playing Horseball for Great Britain
Read article
-
November 09, 2022
Celebrating World Quality Week at Compass
Read article
-
November 03, 2022
Compass Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
Read article
-
November 03, 2022
Compass Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment...
Read article